Tirzepatide Mounjaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL injection, is a prescription medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose). It is not known if Tirzepatide Mounjaro can be used in people who have had pancreatitis. Tirzepatide Mounjaro is not for use in people with type 1 diabetes. It is not known if Tirzepatide Mounjaro is safe and effective for use in children under 18 years of age.
It is a single molecule designed to bind to glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists.2
Tirzepatide Mounjaro represents a different class of medicines introduced for adults with type 2 diabetes. It works differently by directly activating GIP and GLP-1 pathways to help regulate blood sugar.
Dosage:
The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. Follow the
dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6)
and Adverse Reactions (6.1)]. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.
After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.
If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the
current dose.
The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly.
If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the
missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly
scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least
3 days (72 hours).